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Background: Growing compelling evidence from clinical and preclinical studies has demonstrated the primary
role of alterations of glutamatergic transmission in cortical and limbic areas in the pathophysiology of mood
disorders. Chronic antidepressants have been shown to dampen endogenous glutamate release from rat
hippocampal synaptic terminals and to prevent the marked increase of glutamate overflow induced by acute
behavioral stress in frontal/prefrontal cortex. Agomelatine, a new antidepressant endowed with MT1/MT2 agonist
and 5-HT2C serotonergic antagonist properties, has shown efficacy at both preclinical and clinical levels.
Results: Chronic treatment with agomelatine, or with the reference drug venlafaxine, induced a marked decrease
of depolarization-evoked endogenous glutamate release from purified hippocampal synaptic terminals in
superfusion. No changes were observed in GABA release. This effect was accompanied by reduced accumulation
of SNARE protein complexes, the key molecular effector of vesicle docking, priming and fusion at presynaptic
membranes.
Conclusions: Our data suggest that the novel antidepressant agomelatine share with other classes of
antidepressants the ability to modulate glutamatergic transmission in hippocampus. Its action seems to be
mediated by molecular mechanisms located on the presynaptic membrane and related with the size of the
vesicle pool ready for release.
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Compelling evidence suggest that long-term changes in
different brain areas and circuits mediating cognitive
and emotional behaviors represent the biological under-
pinnings of mood and anxiety disorders [1-3]. Since the
vast majority of neurons and synapses in these areas use
glutamate as neurotransmitter [4,5], the glutamatergic
system plays a central role in the pathogenesis of differ-
ent psychiatric disorders and, potentially, appears to be
a final common pathway for the therapeutic action of* Correspondence: daniela.tardito@unimi.it
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reproduction in any medium, provided the orantidepressant agents [3,6-9]. A number of studies have
shown that traditional antidepressants regulate ionotropic
and metabotropic glutamate receptors and modulate
glutamate release and transmission in relevant limbic
and cortical areas (for a discussion, see Ref. [10]). In
this context, several lines of preclinical/clinical re-
search, which have investigated the action of molecules
that directly target the glutamate synapse, are opening
the way for glutamatergic, rapid acting, novel antide-
pressants [6,7].
We have previously found that chronic treatment
with different antidepressants (fluoxetine, desipramine, re-
boxetine) significantly reduced depolarization-evoked
glutamate release from hippocampal synaptic terminals
(synaptosomes) [11]. The above effect was accounted
for by changes in protein phosphorylation [12], in turnal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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assembly of the presynaptic soluble N-ethylmaleimide-
sensitive fusion protein attachment protein receptor
(SNARE) complex, mediating fusion of synaptic vesicles
with presynaptic membrane [11,13]. We have also shown
that acute footshock-stress induces a marked increase
of depolarization-evoked overflow of glutamate from pre-
frontal and frontal cortex synaptosomes, via glucocortic-
oid receptor activation and SNARE complex accumulation
in synaptic membranes. Chronic fluoxetine, desipramine,
venlafaxine or agomelatine completely prevented the in-
crease of glutamate release induced by stress [14].
Agomelatine is a new antidepressant, synergically acting
as an agonist of MT1/MT2 receptors and as an antag-
onist of 5-HT2C receptors [15-19]. Although the effects
of agomelatine on glutamate release in prefrontal and
frontal cortex have been investigated, no data are available
on the effects of this drug in hippocampus. Thus, aims
of the present work were: (1) To assess whether chronic
treatment with agomelatine modulates glutamate release
from superfused hippocampal synaptosomes. (2) To study
whether agomelatine reduces the accumulation of the
presynaptic SNARE complex in hippocampus.
Results
Chronic treatment with agomelatine or venlafaxine
reduces depolarization-evoked release of glutamate from
hippocampal synaptosomes
Synaptosomes were purified from the hippocampus of
chronically drug- or vehicle-treated rats, and exposed in
superfusion to KCl or ionomycin to assess glutamate
and γ-amminobutyric acid (GABA) release. As shown in
Figure 1A, chronic treatment for 3 weeks with either
agomelatine or venlafaxine modified the depolarization-
evoked overflow of glutamate (total release minus basal
outflow). Indeed, both agomelatine and venlafaxine sig-
nificantly reduced (F2,16 = 8.55, p < 0.01) the 15 mM KCl-
induced glutamate overflow (−38% and 49%, respectively).
Interestingly, the release of glutamate induced by the
calcium ionophore ionomycin (0.5 μM), which mobilizes
vesicles from both the recycling and reserve pools (see
[11]), was unaffected by drug treatments, suggesting that
the action of the drugs is mainly confined to vesicles
docked to the presynaptic membrane and primed for
release. Moreover, as previously observed both in hippo-
campus and prefrontal/frontal cortex [11,14,19], the 15
mM KCl-induced overflow of GABA was not modified
by venlafaxine or agomelatine (Figure 1A).
Chronic antidepressant treatments reduce SNARE
complex in hippocampal presynaptic membranes
The core of the presynaptic SNARE complex is formed by
the coiled-coil domain interaction of two membrane pro-
teins (syntaxin-1 and Soluble NSF Attachment Protein-25,SNAP-25) and one vesicle protein (synaptobrevin-2) [20].
A large body of evidence demonstrated that the SNARE
complex mediates the fusion of synaptic vesicles and
neurotransmitter release [21,22].
Because in hippocampus glutamate synaptic terminals
represent the vast majority of total synapses [4], molecular
changes in the presynaptic release apparatus can be likely
correlated with changes in glutamate release. Thus, we
evaluated if the decrease of glutamate release induced
by agomelatine and venlafaxine was associated with altered
assembling of presynaptic SNARE complexes.
The analysis of SNARE complexes in purified presynap-
tic membranes revealed two major syntaxin-1-containing
complexes, migrating at ~100 kDa and ~80 kDa (Figure 1B),
as previously reported [14]. No significant changes were
found in total syntaxin-1 levels (Figure 1C). In line with
the reduction of depolarization-dependent glutamate
release, chronic treatment with both venlafaxine and ago-
melatine significantly reduced the accumulation of 80 kDa
SNARE complex in synaptic membranes (F2,25 = 5.306;
p < 0.05; -23.47% and −19.17% for venlafaxine and ago-
melatine respectively) (Figure 1D). No significant changes
were found in 100 kDa SNARE complex accumulation
(Figure 1E).
Overall, the present findings show that chronic admin-
istration of agomelatine or the reference antidepressant
venlafaxine significantly reduced the endogenous release
of glutamate from hippocampal synaptosomes, as previ-
ously found with other traditional antidepressants [11].
At the same time, both drugs decreased the accumula-
tion of SNARE complexes in presynaptic membranes.
Discussion and conclusion
This work demonstrates that chronic treatment with the
new antidepressant agomelatine, a MT1 and MT2 recep-
tor agonist and 5-HT2C receptor antagonist, as well as
with venlafaxine, a selective serotonin and noradrenaline
reuptake inhibitor, markedly reduces depolarization-evoked
endogenous release of glutamate from hippocampal synap-
tosomes. Interestingly, the depolarization-evoked release
of GABA was not modified, suggesting that both drugs
selectively inhibit glutamatergic release without affecting
GABA transmission. These results are in line with pre-
vious studies, both in vivo and ex vivo, showing similar
effects on glutamatergic transmission of a number of
traditional antidepressants and of agomelatine ([23,24];
discussed and reviewed in Ref. [3] and [10]).
The reduction of glutamate release with no changes
in GABA release suggests an alteration in the balance
between excitatory and inhibitory neurotransmission
that could improve the signal to noise ratio in glutamate
transmission, when it becomes compromised by excessive
release. In this regard, we have demonstrated that chronic
treatment with different classes of antidepressants, includ-
Figure 1 Effect of chronic treatment with agomelatine or venlafaxine on depolarization-evoked glutamate and GABA release
and on SNARE complex accumulation in hippocampal synaptosomes. A) 15 mM KCl-evoked glutamate and GABA release and 0.5 mM
ionomycin-evoked glutamate release from hippocampal synaptosomes of rats chronically treated with vehicle (CNT), agomelatine (AGO) or
venlafaxine (VFX). B) Representative Western Blot of SNARE complexes in hippocampal synaptosomes visualized with a monoclonal antibody for
syntaxin-1. The two SNARE complexes at approximately 100 and 80 kDa and syntaxin-1 monomer are indicated by arrows. Each single SNARE
complex was normalized on monomeric syntaxin-1 in the same lane. C) Quantitation of syntaxin-1 in CNT and rats chronically treated with VFX
or AGO. D) Quantitation of normalized 100 kDa SNARE complex in CNT rats and rats chronically treated with VFX or AGO. E) Quantitation of
normalized 80 kDa SNARE complex in CNT rats, and rats chronically treated with VFX or AGO. All data are expressed as mean ± SEM. * p<0.05,
** p<0.01 vs. CNT rats, Newman-Keuls post-hoc tests following one-way ANOVA (n = 6–10 rats/group in duplicate).
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marked increase of depolarization-evoked glutamate re-
lease from prefrontal and frontal cortex synaptosomes
induced by acute stress [14,19].
Another intriguing result of this study is that, despite
chronic agomelatine inhibited glutamate release evoked
by 15 mM KCl depolarization, it had no effect on releaseinduced by 0.5 mM ionomycin. Indeed, if it is generally
agreed that electrical/chemical depolarization mainly in-
duces the fusion of vesicles of the readily releasable pool
(RRP) [25], ionomycin also promotes calcium-dependent
fusion of vesicles, but mainly from the reserve pool.
Therefore, our results suggest that agomelatine may
selectively affect the RRP of vesicles, thereby altering a
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In line with this hypothesis, we found that the reduction
of glutamate release induced by chronic agomelatine and
venlafaxine was accompanied by reduced accumulation
of SNARE complexes in synaptic membranes (the fraction
of synaptosomes containing the RRP). These data are in
line with our previous results showing that traditional
antidepressant-induced reduction of glutamate release is
accounted for by changes in protein-protein interactions
regulating the assembly of the SNARE complex [11],
and by reduction of complex accumulation in presynaptic
membranes [13]. However, contrary to previous results
with traditional antidepressants (2 weeks of treatment)
[11], here we did not find major changes in the expression
of syntaxin-1 after 3 weeks of treatment with agomelatine
or venlafaxine. Because the same result was obtained
with both drugs, we suggest that the difference from
other antidepressants is probably due to the different
timing of drug-treatment (3 vs 2 weeks). However, the
main finding is that, after treatment for 3 weeks, ago-
melatine and venlafaxine still reduced both the accumula-
tion of SNARE complexes at the level of the RRP and
the physiological release of glutamate.
Indeed, the SNARE complex and associated proteins
play a critical role in vesicle docking, priming, fusion and
synchronization of neurotransmitter release at presynaptic
membranes and it was established that the SNARE com-
plex corresponds to the minimal machinery for membrane
fusion in eukaryotic cells, forming a stable complex
that make the vesicles competent for fusion [21,22,26].
Therefore, a reduction of SNARE complex accumulation
in synaptic membranes is consistent with reduced neuro-
transmitter release.
In conclusion, the present study demonstrated that
chronic agomelatine dampens hippocampal glutamate
neurotransmission, a likely component of the therapeutic
action of antidepressants. The intriguing finding of re-
duced accumulation of SNARE complexes in presynaptic
membranes suggests selected mechanisms in the exo-
cytotic machinery as possible molecular targets of these
drugs.
Methods
Animals and treatments
Adult male Sprague–Dawley rats (170–200 g) were pur-
chased from Charles River (Calco, Italy). Animals were
kept at constant temperature (22°C) with a regular 12 h
light/dark cycle (light-off at 7 pm). The rats were housed
in groups of four with ad libitum access to food and
water. Rats were treated with agomelatine (40 mg/kg i.p.),
venlafaxine (10 mg/kg i.p.) or vehicle (hidroxyethylcel-
lulose, 1%, 1 ml/Kg, i.p.) for 21 days. All drugs were ad-
ministered at 5.00 pm (2 h before the start of the dark
cycle, 7 pm). Animals were sacrified 16 h after the lastdrug administration, and the hippocampus (HPC) was
quickly removed.
All animal procedures were conducted according to
current regulations for animal experimentation in Italy
(Decreto Legislativo 116/1992) and the European Union
(European Communities Council Directive 86/609/EEC)
and following authorization by the Italian Ministry of
Health to the University of Milano for experimental use
of animals (Decreto Legislativo 295/2012-A).
Preparation of purified synaptosomes
Purified synaptic terminals (synaptosomes) were prepared
by centrifugation on Percoll gradients [27], with minor
modifications as previously described [14,28]. Purity of
synaptosomes and other subcellular fractions were evalu-
ated by electron microscopy and by measuring subcellular
distribution of protein markers (not shown), as previously
reported [29].
When used for neurotransmitter release experiments,
synaptosomes were resuspended in physiological medium
with the following composition: 140 mM NaCl, 3 mM
KCl, 1.2 mM MgSO4, 1.2 mM CaCl2, 1.2 mM NaH2PO4,
5 mM NaHCO3, 10 mM glucose, 10 mM HEPES, pH 7.2–
7.4. For western blotting experiments, synaptosomes were
resuspended in lysis buffer: 120 mM NaCl, 20 mM HEPES
pH 7.4, 0.1 mM EGTA, 0.1 mM DTT, containing 20 mM
NaF, 5 mM Na2PO4, 1 mM Na2VO4, and 2 mg/ml of pro-
tease inhibitor cocktail (Sigma-Aldrich, Milan, Italy). Fur-
ther fractionation of freshly purified synaptosomes into
synaptic membranes was carried out by differential centri-
fugation as previously reported [14].
Endogenous glutamate and GABA release experiments
Endogenous neurotransmitter release was measured as
previously reported [19,30]. Synaptosomes (about 100 μg
of protein) were layered on microporous filters at the bot-
tom of a set of parallel superfusion chambers maintained
at 37°C [30]. Superfusion was started at a rate of 0.5 ml/
min with standard medium. After 36 min of superfusion,
samples were collected according to the following scheme:
two 3-min samples (t = 36–39 min and t = 45–48 min;
basal outflow) before and after one 6-min sample (t =
39–45 min; stimulus-evoked release). A 90-sec period of
stimulation was applied at t = 39 min, after the first sam-
ple has been collected. Stimulation of synaptosomes
was performed with 0.5 μM ionomycin or 15 mM KCl,
the latter substituting for an equimolar concentration
of NaCl.
Fractions collected were analyzed for endogenous glu-
tamate and GABA content. Endogenous glutamate and
GABA were measured by high performance liquid chro-
matography analysis. Amino acid release was expressed
as nmol/mg of protein. The stimulus-evoked overflow
was estimated by subtracting transmitter content of the
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the 6-min sample collected during and after the depo-
larization pulse (stimulus-evoked release). Drug treatment
effects were evaluated by comparing the stimulus-evoked
overflow in drug-treated animals vs. that calculated in
vehicle treated rats. Appropriate controls were always
run in parallel.
Measurement of SNARE complex in isolated
presynaptic membranes
For detection of SDS-resistant SNARE complexes, Western
blotting was performed on samples of electrophoresed
presynaptic membranes (non-boiled before gel loading)
[14], incubating PVDF membranes containing blotted
proteins with monoclonal antibodies for syntaxin-1 1:5000
(Sigma-Aldrich). The membranes were incubated with
anti-mouse secondary antibody 1:4000 (Sigma-Aldrich),
and immunoreactive bands revealed with ECL™ (GE
Healthcare, Italy). Membranes were immediately exposed
to Hyperfilm ECL™ films (GE Healthcare), and images
acquired with the Quantity One software and GelDoc
imaging system (Bio-Rad Laboratories, Italy). All bands
used were within linear range of standard curves, and
normalized for syntaxin-1 monomer levels in the same
membrane. Standardization and quantitation of digita-
lized images were performed with Quantity One soft-
ware (Bio-Rad).
Statistical analysis
Statistical analysis was carried out by one-way analysis of
variance (ANOVA) followed by Newman-Keuls post-hoc
test. Significance was assumed at p < 0.05. Statistical ana-
lysis of the data was carried out using GraphPad Prism4
(GraphPad Software Inc., USA). Data are expressed as
mean ± SEM.
Abbreviations
ANOVA: Analysis of variance; GABA: γ-Amminobutyric acid; MT1: MT2,
Melatonergic receptor1 and 2; RRP: Readily releasable pool; SNAP-25: Soluble
NSF Attachment Protein-25; SNARE: Soluble N-ethylmaleimide-sensitive
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